Trial Profile

Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTI 101 (Primary)
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions

Most Recent Events

21 Aug 2026 Planned number of patients changed from 18 to 24.
27 May 2026 Status changed from active, no longer recruiting to recruiting.
17 Mar 2026 Given protocol has been amended as above- 1) status changed to active, no longer recruiting. 2) Planned primary completion and planned end date changed to 30 Jun 2029. 3) Open label design has been amended. 4) Primary endpoints has been amended. 5) Number of treatment arms has been changed from 2 to 4. 6) Actual patient number is 5.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com